Bristol-Myers Squibb (NYSE:BMY) Shares Sold by SFE Investment Counsel

SFE Investment Counsel lessened its stake in Bristol-Myers Squibb (NYSE:BMY) by 19.5% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 53,901 shares of the biopharmaceutical company’s stock after selling 13,030 shares during the period. SFE Investment Counsel’s holdings in Bristol-Myers Squibb were worth $2,766,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the stock. Riversedge Advisors LLC grew its position in shares of Bristol-Myers Squibb by 3.2% in the third quarter. Riversedge Advisors LLC now owns 5,691 shares of the biopharmaceutical company’s stock valued at $330,000 after purchasing an additional 178 shares during the last quarter. Vicus Capital grew its position in shares of Bristol-Myers Squibb by 3.9% in the third quarter. Vicus Capital now owns 4,824 shares of the biopharmaceutical company’s stock valued at $280,000 after purchasing an additional 179 shares during the last quarter. Front Row Advisors LLC grew its position in shares of Bristol-Myers Squibb by 17.5% in the fourth quarter. Front Row Advisors LLC now owns 1,222 shares of the biopharmaceutical company’s stock valued at $88,000 after purchasing an additional 182 shares during the last quarter. Cassia Capital Partners LLC lifted its stake in shares of Bristol-Myers Squibb by 2.3% during the third quarter. Cassia Capital Partners LLC now owns 7,931 shares of the biopharmaceutical company’s stock valued at $460,000 after buying an additional 182 shares during the period. Finally, Lindbrook Capital LLC lifted its stake in shares of Bristol-Myers Squibb by 2.3% during the third quarter. Lindbrook Capital LLC now owns 8,060 shares of the biopharmaceutical company’s stock valued at $468,000 after buying an additional 182 shares during the period. Institutional investors and hedge funds own 76.41% of the company’s stock.

Bristol-Myers Squibb Price Performance

Shares of NYSE:BMY traded up $0.28 during trading on Thursday, reaching $48.12. The company had a trading volume of 6,708,956 shares, compared to its average volume of 15,720,609. The firm’s fifty day moving average is $51.26 and its 200 day moving average is $51.59. The firm has a market capitalization of $97.53 billion, a PE ratio of 12.46, a price-to-earnings-growth ratio of 1.49 and a beta of 0.39. Bristol-Myers Squibb has a twelve month low of $47.58 and a twelve month high of $70.93. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.31 and a current ratio of 1.43.

Bristol-Myers Squibb (NYSE:BMY) last released its earnings results on Friday, February 2nd. The biopharmaceutical company reported $1.70 EPS for the quarter, beating the consensus estimate of $1.55 by $0.15. Bristol-Myers Squibb had a net margin of 17.83% and a return on equity of 50.95%. The business had revenue of $11.48 billion during the quarter, compared to analyst estimates of $11.19 billion. During the same period in the prior year, the business earned $1.82 earnings per share. The business’s quarterly revenue was up .6% on a year-over-year basis. On average, equities analysts forecast that Bristol-Myers Squibb will post 6.47 EPS for the current year.

Bristol-Myers Squibb Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 1st. Shareholders of record on Friday, April 5th will be given a $0.60 dividend. This represents a $2.40 annualized dividend and a yield of 4.99%. The ex-dividend date is Thursday, April 4th. Bristol-Myers Squibb’s payout ratio is presently 62.18%.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the stock. Societe Generale downgraded shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research note on Monday, March 11th. Redburn Atlantic lowered shares of Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and lowered their price target for the company from $77.00 to $54.00 in a report on Tuesday, February 6th. StockNews.com lowered shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a report on Monday. Wells Fargo & Company raised their price target on shares of Bristol-Myers Squibb from $51.00 to $52.00 and gave the company an “equal weight” rating in a report on Thursday. Finally, William Blair reaffirmed a “market perform” rating on shares of Bristol-Myers Squibb in a report on Monday, April 1st. One analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $61.18.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.